Pediatric Burden of Seasonal Influenza and the Impact of Vaccination: A Structured Review

Background: Seasonal influenza remains a leading cause of severe respiratory illness in children worldwide. Each year, ۳-۵ million cases of severe influenza occur, resulting in up to ۶۵۰,۰۰۰ respiratory deaths-with a disproportionate burden on children under ۵ years of age. Beyond the clinical toll, pediatric hospitalizations drive substantial economic costs through extended stays, intensive care use, antimicrobial therapy, and school absenteeism. Objectives: This review specifically targets the pediatric dimensions of seasonal influenza by: Characterizing epidemiological patterns in children; Evaluating vaccine effectiveness in reducing pediatric morbidity and healthcare utilization.; and Presenting tailored recommendations for pediatric influenza prevention in the ۲۰۲۵-۲۰۲۶ season. Methods: A systematic search of peer-reviewed literature, clinical trial registries, and pediatric health-organization guidelines was performed. We extracted age-stratified data on incidence, hospitalization and ICU admission rates in children, vaccine effectiveness against severe pediatric outcomes, and pediatric influenza-associated mortality. Vaccine composition and pediatric dosing schedules from bodies such as the American Academy of Pediatrics were also examined. Results: Epidemiology in Children: Children ۵ years experience hospitalization rates as high as ۴۴.۱ per ۱۰,۰۰۰, representing the peak burden across all age groups. In pediatric cohorts, vaccination lowers risk of severe illness by up to ۷۵%, PICU admissions by up to ۷۴%, and emergency-department visits by up to ۵۰%. Children with underlying conditions see mortality risk cut by over ۵۰%. Raising vaccination coverage by just ۵-۱۵% among school-aged children could cut overall influenza cases by more than ۱۰% and avert tens of thousands of pediatric hospitalizations annually. Universal vaccination for all children ≥ ۶ months is strongly endorsed, with priority on those ۵ years, those with chronic diseases, and pediatric healthcare providers. The proposed quadrivalent vaccine includes A/Victoria/۴۸۹۷/۲۰۲۲ (H۱N۱), A/Croatia/۱۰۱۳۶RV/۲۰۲۳ (H۳N۲), B/Austria/۱۳۵۹۴۱۷/۲۰۲۱ (Victoria lineage), and B/Phuket/۳۰۷۳/۲۰۱۳ (Yamagata lineage). Conclusion: Targeted pediatric vaccination remains the cornerstone strategy to mitigate seasonal influenza's clinical and economic burden. Expanding delivery in schools, community clinics, and non-traditional settings—and achieving high uptake among young children—are critical to reducing pediatric hospitalizations, PICU admissions, and mortality.